Some cybersecurity researchers say it’s too early to worry about AI-orchestrated cyberattacks. Others say it could already be happening.

A marriage of formal methods and LLMs seeks to harness the strengths of both.

Competitive advantage will not come from adding more tools to an already fragmented stack. It will come from strengthening the foundation—aligning people, processes and data—so firms can unlock the ...

The recent Andromeda update, the fastest and most advanced iteration to date of Meta’s ad-retrieval system, has dramatically changed the rhythm of Meta Ads. Delivery cycles are faster, creative gets ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...